CA2823972C - Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions - Google Patents
Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions Download PDFInfo
- Publication number
- CA2823972C CA2823972C CA2823972A CA2823972A CA2823972C CA 2823972 C CA2823972 C CA 2823972C CA 2823972 A CA2823972 A CA 2823972A CA 2823972 A CA2823972 A CA 2823972A CA 2823972 C CA2823972 C CA 2823972C
- Authority
- CA
- Canada
- Prior art keywords
- liquid medium
- suspension
- drug
- acetone
- diafiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431942P | 2011-01-12 | 2011-01-12 | |
| US61/431,942 | 2011-01-12 | ||
| PCT/EP2012/050336 WO2012095439A1 (en) | 2011-01-12 | 2012-01-11 | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2823972A1 CA2823972A1 (en) | 2012-07-19 |
| CA2823972C true CA2823972C (en) | 2019-05-28 |
Family
ID=45478323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2823972A Active CA2823972C (en) | 2011-01-12 | 2012-01-11 | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9066864B2 (enExample) |
| EP (1) | EP2663287A1 (enExample) |
| JP (1) | JP5934719B2 (enExample) |
| CN (1) | CN103347499B (enExample) |
| AU (1) | AU2012206621B2 (enExample) |
| BR (1) | BR112013016851B1 (enExample) |
| CA (1) | CA2823972C (enExample) |
| MX (1) | MX346749B (enExample) |
| SG (2) | SG10201807631SA (enExample) |
| WO (1) | WO2012095439A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6478959B2 (ja) * | 2016-09-07 | 2019-03-06 | 株式会社富士薬品 | 粒子含有組成物を製造するためのシステム及び方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4790912B2 (ja) | 1999-05-12 | 2011-10-12 | メタボリックス，インコーポレイテッド | ポリヒドロキシアルカノエートを精製するための方法 |
| EP1225968B1 (en) | 1999-09-17 | 2006-04-05 | Alfa Laval Nakskov A/S | A method and an apparatus for continuous cross-flow diafiltration |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| WO2003055469A1 (en) * | 2001-12-21 | 2003-07-10 | Celator Technologies Inc. | Improved polymer-lipid delivery vehicles |
| WO2003063877A1 (en) * | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
| PL208585B1 (pl) * | 2002-10-25 | 2011-05-31 | Intervet Int Bv | Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca cefquinom, sposób jej wytwarzania i zastosowanie cefquinomu |
| ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
| CN102811743B (zh) * | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
-
2012
- 2012-01-11 WO PCT/EP2012/050336 patent/WO2012095439A1/en not_active Ceased
- 2012-01-11 SG SG10201807631SA patent/SG10201807631SA/en unknown
- 2012-01-11 BR BR112013016851-0A patent/BR112013016851B1/pt active IP Right Grant
- 2012-01-11 CA CA2823972A patent/CA2823972C/en active Active
- 2012-01-11 AU AU2012206621A patent/AU2012206621B2/en active Active
- 2012-01-11 EP EP12700273.1A patent/EP2663287A1/en not_active Withdrawn
- 2012-01-11 SG SG2013053764A patent/SG191963A1/en unknown
- 2012-01-11 US US13/979,231 patent/US9066864B2/en active Active
- 2012-01-11 CN CN201280005390.0A patent/CN103347499B/zh active Active
- 2012-01-11 JP JP2013548820A patent/JP5934719B2/ja active Active
- 2012-01-11 MX MX2013008118A patent/MX346749B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US9066864B2 (en) | 2015-06-30 |
| MX346749B (es) | 2017-03-29 |
| WO2012095439A1 (en) | 2012-07-19 |
| SG191963A1 (en) | 2013-08-30 |
| JP2014502624A (ja) | 2014-02-03 |
| US20130281425A1 (en) | 2013-10-24 |
| SG10201807631SA (en) | 2018-10-30 |
| EP2663287A1 (en) | 2013-11-20 |
| CN103347499B (zh) | 2017-04-05 |
| AU2012206621B2 (en) | 2017-04-27 |
| MX2013008118A (es) | 2013-08-12 |
| CN103347499A (zh) | 2013-10-09 |
| BR112013016851B1 (pt) | 2021-08-31 |
| CA2823972A1 (en) | 2012-07-19 |
| BR112013016851A2 (pt) | 2016-10-04 |
| AU2012206621A1 (en) | 2013-07-04 |
| JP5934719B2 (ja) | 2016-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7203078B2 (ja) | 粒子の連続製造方法 | |
| CA2868676C (en) | Production of near monodisperse particles using milling and membrane separation | |
| CA2956732C (en) | A method of preparing amorphous solid dispersion in submicron range by co-precipitation | |
| US7468151B2 (en) | Method for the preparation of purified microparticles | |
| AU2012206621B2 (en) | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions | |
| WO2012095438A1 (en) | Particles and suspensions of cephalosporin antibiotics | |
| CN118453513B (zh) | 一种β-内酰胺酶抑制剂液体制剂的制备工艺 | |
| CN120379751A (zh) | 提供用于形成微囊泡的脂质体溶液的方法 | |
| Ohri | A preliminary investigation of the sterile-filterability of BCS class II drug nanosuspensions prepared via wet stirred media milling | |
| AU2006212177A1 (en) | Method of purifying a surfactant by ultrafiltration | |
| JPWO2004113424A1 (ja) | 難水溶性物質と水溶性高分子との共沈物の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170111 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241209 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251209 |